Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Middle East respiratory syndrome coronavirus vaccine - GeneOne Life Sciences/Inovio Pharmaceuticals

Drug Profile

Middle East respiratory syndrome coronavirus vaccine - GeneOne Life Sciences/Inovio Pharmaceuticals

Alternative Names: GLS 5300; INO-4301; INO-4700; MERS vaccine - GeneOne Life Sciences/Inovio Pharmaceuticals

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer GeneOne Life Science; Inovio Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Antivirals; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Middle East respiratory syndrome coronavirus

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for phase-I development in Middle-East-respiratory-syndrome-coronavirus(Prevention) in USA (IM)
  • 05 Sep 2018 Inovio Pharmaceuticals plans a phase II trial for Middle East respiratory syndrome (Prevention) in the Middle East and Africa (Intradermal), in 2019
  • 27 Jun 2018 Inovio Pharmaceuticals and GeneOne Life Science plan a phase I/II trial for Middle east respiratory syndrome in South Korea, in the third quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top